Topical Losartan Treatment of Herpes Simplex Virus- or Varicella-Zoster Virus-Induced Corneal Scarring: A Case Series
Case Reports in Ophthalmology · 11.03.2025 · 16 (1) · 281-289
DOI: 10.1159/000545215 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Ophthalmology, online erschienen am 11.03.2025. Verfasst von Barbara A L Dutra und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Cole Eye Institute, The Cleveland Clinic, Cleveland, OH, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Topical losartan has emerged as a promising therapeutic option for preventing and treating corneal scarring fibrosis. Its mechanism of action involves the inhibition of ERK-mediated signaling in the noncanonical TGF-beta pathways, promoting apoptosis of myofibroblasts and facilitating a return of corneal transparency. While numerous studies in rabbits and several human case reports have demonstrated its efficacy and safety, published data on its use in clinical scenarios remain limited. This study presents 3 cases where topical losartan successfully treated corneal scarring induced by herpes simplex virus (HSV) or varicella-zoster virus (VZV) keratitis. Case Presentations: Three patients (ages 40, 38, 15 years) with corneal scarring and vision loss from HSV or VZV keratitis were treated with topical 0.8 mg/mL losartan 6 times a day for 4–9 months, depending on the clinical response, after failing traditional management with corticosteroids. Best spectacle-corrected vision and slit-lamp corneal opacity improved in each case. Anterior segment OCT documented improved stromal opacity in 1 case.
Conclusions
Topical losartan, a known inhibitor of fibrotic TGF-beta signaling, is potentially an effective alternative in the treatment of stromal scarring fibrosis caused by corneal HSV and VZV infections. Patients with HSV- or VZV keratitis-induced corneal scarring may be ideal candidates for planned clinical trials of the efficacy and safety of topical losartan treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Cole Eye Institute, The Cleveland Clinic, Cleveland, OH, USA.
- Department of Ophthalmology at University of Sao Paulo, Sao Paulo, Brazil.
- Department of Ophthalmology at the University of Missouri, Kansas City, MO, USA.
- Ribeirao Preto Ophthalmological Hospital, Ribeirao Preto, Brazil.
Zitieren
APA
Dutra, B. A. L., Drew-Bear, L. E., Herretes, S. P., Arroyo, D., de Oliveira, R. C., Sampaio, L. P., Santhiago, M. R., & Wilson, S. E. (2025). Topical Losartan Treatment of Herpes Simplex Virus- or Varicella-Zoster Virus-Induced Corneal Scarring: A Case Series. Case Reports in Ophthalmology, 16(1), 281-289. https://doi.org/10.1159/000545215
Vancouver
Dutra BAL, Drew-Bear LE, Herretes SP, Arroyo D, de Oliveira RC, Sampaio LP, et al. Topical Losartan Treatment of Herpes Simplex Virus- or Varicella-Zoster Virus-Induced Corneal Scarring: A Case Series. Case Reports in Ophthalmology. 2025;16(1):281-289. doi:10.1159/000545215
BibTeX
@article{Dutra2025,
author = {Dutra, Barbara A L and Drew-Bear, Laura E and Herretes, Samantha P and Arroyo, Danielle and de Oliveira, Rodrigo Carlos and Sampaio, Lycia Pedral and Santhiago, Marcony R and Wilson, Steven E},
title = {Topical Losartan Treatment of Herpes Simplex Virus- or Varicella-Zoster Virus-Induced Corneal Scarring: A Case Series},
journal = {Case Reports in Ophthalmology},
year = {2025},
volume = {16},
number = {1},
pages = {281--289},
doi = {10.1159/000545215}
}
EUVIMED